Solid Biosciences Llc Stock Performance
| SLDB Stock | USD 5.36 0.27 5.30% |
On a scale of 0 to 100, Solid Biosciences holds a performance score of 5. The entity has a beta of 1.99, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Solid Biosciences will likely underperform. Please check Solid Biosciences' semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Solid Biosciences' existing price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Solid Biosciences LLC are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady fundamental indicators, Solid Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.3 | Five Day Return (4.29) | Year To Date Return 37.44 | Ten Year Return (98.42) | All Time Return (98.42) |
Last Split Factor 1:15 | Last Split Date 2022-10-28 |
1 | Disposition of 3255 shares by Smith Ian F of Solid Biosciences subject to Rule 16b-3 | 01/03/2025 |
2 | Disposition of 11250 shares by Tan Kevin of Solid Biosciences subject to Rule 16b-3 | 01/08/2025 |
3 | Cantor Fitzgerald Comments on SLDB FY2025 Earnings - MarketBeat | 01/22/2025 |
4 | Disposition of 388 shares by Ilan Ganot of Solid Biosciences subject to Rule 16b-3 | 01/27/2025 |
5 | Disposition of 144 shares by Ilan Ganot of Solid Biosciences at 3.1096 subject to Rule 16b-3 | 01/28/2025 |
6 | Disposition of 1142 shares by Ilan Ganot of Solid Biosciences at 5.2999 subject to Rule 16b-3 | 01/30/2025 |
7 | Acquisition by Alexander Cumbo of 401600 shares of Solid Biosciences subject to Rule 16b-3 | 01/31/2025 |
8 | Acquisition by Jessie Hanrahan of 110500 shares of Solid Biosciences subject to Rule 16b-3 | 02/11/2025 |
9 | Acquisition by Ilan Ganot of 3883 shares of Solid Biosciences subject to Rule 16b-3 | 02/12/2025 |
10 | Disposition of 4861 shares by Ilan Ganot of Solid Biosciences subject to Rule 16b-3 | 02/13/2025 |
11 | Disposition of 1711 shares by Ilan Ganot of Solid Biosciences at 3.96 subject to Rule 16b-3 | 02/14/2025 |
12 | Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 | 02/18/2025 |
13 | Solid Biosciences sees 20.15m stock purchase by Perceptive Advisors - Investing.com | 02/21/2025 |
14 | Acquisition by Freed Martin I of 34400 shares of Solid Biosciences at 7.51 subject to Rule 16b-3 | 02/28/2025 |
15 | Is Solid Biosciences Inc. Among Stocks With At Least 20 Million In Insider Spending Recently | 03/05/2025 |
16 | Wall Street Analysts Believe Solid Biosciences Could Rally 198.18 percent Heres is How to Trade | 03/07/2025 |
17 | FY2026 Earnings Forecast for SLDB Issued By William Blair - Defense World | 03/10/2025 |
18 | Acquisition by Kahn Clare of 1860 shares of Solid Biosciences at 5.3357 subject to Rule 16b-3 | 03/11/2025 |
19 | Solid Biosciences to Present at the 2025 Muscular Dystrophy Association Clinical ... | 03/12/2025 |
20 | Acquisition by Howton David T of 58750 shares of Solid Biosciences subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 75.8 M |
Solid |
Solid Biosciences Relative Risk vs. Return Landscape
If you would invest 446.00 in Solid Biosciences LLC on December 17, 2024 and sell it today you would earn a total of 63.00 from holding Solid Biosciences LLC or generate 14.13% return on investment over 90 days. Solid Biosciences LLC is currently generating 0.4742% in daily expected returns and assumes 7.4686% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Solid, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Solid Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Solid Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Solid Biosciences LLC, and traders can use it to determine the average amount a Solid Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0635
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SLDB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.47 actual daily | 66 66% of assets are less volatile |
Expected Return
| 0.47 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 5 95% of assets perform better |
Based on monthly moving average Solid Biosciences is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Solid Biosciences by adding it to a well-diversified portfolio.
Solid Biosciences Fundamentals Growth
Solid Stock prices reflect investors' perceptions of the future prospects and financial health of Solid Biosciences, and Solid Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Solid Stock performance.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 269.7 M | ||||
| Shares Outstanding | 77.49 M | ||||
| Price To Book | 2.87 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | (96.43 M) | ||||
| EBITDA | (129.73 M) | ||||
| Net Income | (124.7 M) | ||||
| Cash And Equivalents | 162.88 M | ||||
| Cash Per Share | 1.44 X | ||||
| Total Debt | 24.18 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 7.85 X | ||||
| Book Value Per Share | 3.39 X | ||||
| Cash Flow From Operations | (100.01 M) | ||||
| Earnings Per Share | (3.06) X | ||||
| Market Capitalization | 394.44 M | ||||
| Total Asset | 188.66 M | ||||
| Retained Earnings | (783.45 M) | ||||
| Working Capital | 127.05 M | ||||
About Solid Biosciences Performance
By analyzing Solid Biosciences' fundamental ratios, stakeholders can gain valuable insights into Solid Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Solid Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Solid Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 33.64 | 29.90 | |
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (0.91) | (0.86) |
Things to note about Solid Biosciences LLC performance evaluation
Checking the ongoing alerts about Solid Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Solid Biosciences LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Solid Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (124.7 M) with loss before overhead, payroll, taxes, and interest of (96.43 M). | |
| Solid Biosciences LLC currently holds about 162.88 M in cash with (100.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Solid Biosciences to Present at the 2025 Muscular Dystrophy Association Clinical ... |
- Analyzing Solid Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Solid Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Solid Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Solid Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Solid Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Solid Biosciences' stock. These opinions can provide insight into Solid Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Solid Stock analysis
When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |